Monthly Archives: March 2017

Local Pest Control And Termite Company in McAlester Hires Ultimate People Person

Local Pest & Termite Company Mike’s Pest Control in McAlester, OK is excited to announce the addition of a new professional staff member to its team.

McAlester, United States – March 24, 2017 /PressCable/ —

March 24, 2017 – Mike’s Pest Control in McAlester, OK, is pleased to announce the addition of a new staff to its team. Courtney Burns who has worked in various administrative capacities is poised to serve as the Customer relations, Marketing/Sales expert in our organization. In view of our company’s quest to strengthen our market dominance, we are consistently aligning our personnel to meet contemporary realities. One of the core operating values is to ensure that the customers of Mike’s Pest Control have the best service experience whenever they come into our world.

The personal and professional qualifications of Courtney Burns will birth a sharper operating system in our stream. We are pleased to state that Courtney got her CNA 15 years ago and worked for Walnut Grove for 5 years. She worked at Colonial Lodge before going to college. During her time in school, she worked for Heritage Hills. Courtney graduated with an Associate Degree and is majoring in Health Sciences. She served as a CNAC at Heritage Hills where she received Social Service License and worked as a Social Service Director for three and half years. In the Social Service Position, she performed Marketing and Admission functions.

In July, 2016, her dexterity caused her to rise to the position of a Business Office Manager. This enabled her to perform more broad-based roles such as Employee Orientation, Payroll, Billing, worked with Social Security and DHS. The depth of her expertise makes her a sublime addition to the Mike’s Pest Control Personnel. Over the years, Courtney has helped to shape the operations of our organization but she is coming on-board to help raise the bar of service in a full capacity. In her words, Courtney Burns said – “I am very blessed and excited to be a part of my family business.”

The owner of Mike’s Pest Control, Shane Burns stated that – “We are pleased to announce that Courtney Burns is joining the team at Mike’s Pest Control, Inc. She will bring great customer relations and marketing/sales skills to our team.” He further said that this is a timely addition to help the company drive its growth and expansion objectives. The company which has been professionally run for many years is looking to keep attracting top talent into its fold.

About Mike’s Pest Control

Mike’s Pest Control is a leader in its niche that has been serving the McAlester area for many years. This family run business which has an extensive range of service caters to all forms of pest control and termite management needs of their customers. In line with their strict adherence to safety, health and the environment issues; they ensure that they use substances that are aligned to globally accepted standards. The large client base of this business has continued to grow and they are one of the top line pest control businesses in OK. Mike’s Pest Control has core values such as Integrity, Resilience, Humility and Empathy at the heart of its operations.

Learn more by visiting: http://mpcpestcontrol.com

Contact Info:
Name: Shane Burns
Organization: Mike’s Pest Control
Address: 2140 South George Nigh Expressway, McAlester, Oklahoma 74501, United States
Phone: +1-918-423-2458

For more information, please visit http://mpcpestcontrol.com

Source: PressCable

Release ID: 180683

SITO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Sito Mobile, Ltd. and a Lead Plaintiff Deadline of April 18, 2017

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Sito Mobile, Ltd. (“Sito”) (NASDAQ: SITO) securities between February 9, 2016, and January 2, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra/sito-mobile-ltd. There is no cost or obligation to you.

According to the complaint, throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Sito’s growth of bookings would not propel the Company’s fourth fiscal quarter 2016 media placement revenues and revenue growth to the level represented during the Class Period; (ii) Sito was aware that the election would impact the Company’s fourth fiscal quarter 2016 revenue, (iii) clients’ campaign spending and media placement revenues in the fourth quarter 2016 was highly dependent on the elections; (iv) the Company’s growth in media placement revenues would not occur in the fourth fiscal quarter 2016; (v) as a result of the foregoing, the Company’s statements, as well as Defendants’ statements, about Sito’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Sito, you have until April 18, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/sito-mobile-ltd.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 458127

EntirelyBiz Announces Toshiba TSD Upgrade Program

CLINTON TOWNSHIP, MI / ACCESSWIRE / March 24, 2017 / EntirelyBiz, a provider of cloud and on-premises business phone systems, today announced an upgrade program for Toshiba TSD customers. This announcement comes on the heels of Toshiba announcing it would be “winding down” its Telecommunication Systems Division (TSD).

On March 21st, Toshiba’s Telecommunication Systems Division (TSD) announced to its dealers they are winding-down business immediately, leaving their entire customer base scrambling for replacement systems. Toshiba TSD is providing its customers and partners sixty days’ notice and that’s it, game over!

Fortunately, EntirelyBiz is offering a path forward for Toshiba TSB customers. For a limited time, EntirelyBiz is offering Toshiba TSD customers up to 50% off when they upgrade to our cloud or on-premises business phone systems.

“We’ve been offering business phone systems for 30 years and Toshiba’s announcement is the latest domino to fall in the traditional telecom market,” said Michael Meldrum, CEO of EntirelyBiz. “We feel for customers being abandoned by large companies no longer interested in supporting them. We want to provide these customers a path forward to a more secure future.”

EntirelyBiz’s Toshiba TSD upgrade program offers customers up to 50% off an upgrade to a cloud subscription or any of its on-premises business phone systems. EntirelyBiz is committed to providing Toshiba’s telecommunication customers a path forward, even if this giant corporation is not. Details of the plan can be found here.

“We’ve developed our reputation on providing an extremely high-level of customer support,” said Meldrum. “We have a network of vendors, suppliers, and partners that enables us to deliver quality support for business phone systems and associated services to mid-size and small businesses throughout North America.”

About EntirelyBiz:

EntirelyBiz is an IT managed services provider offering structured cabling, network infrastructure, cloud migrations, mobility, business phone systems, and business security systems to mid-size and small businesses. EntirelyBiz will keep your business premises, network, communications, and IT systems secure, optimized, and available. We’re big enough to offer the technology and services you need, while acting small, providing local implementation and ongoing support. Learn more at www.entirelybiz.com, or contact us at 586-439-2000. EntirelyBiz is a wholly owned brand of Complete Interactive Technologies.

SOURCE: Complete Interactive Technologies

ReleaseID: 458130

Memantine Market Share, Trend, Demand and Key Manufacturers Analysis and Forecast to 2022

ReportsWeb.com added “Global Memantine Market Research Report 2017” to its vast collection of research Database. The report is spread across 114 pages and supported by 11 company leaders.

March 24, 2017 /MarketersMedia/ —

The Global Memantine Market Research Report 2017 is a professional and in-depth study on the current state of the Memantine industry. In a word, This report studies Memantine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer. Key companies included in this research are Allergan, Lundbeck, Merz Pharma and Daiichi Sankyo.

Browse complete report @ http://www.reportsweb.com/global-memantine-market-research-report-2017

Market Segment by Region, this report splits Global into several key Region, with sales, revenue, market share and growth rate of Memantine in these regions, from 2011 to 2022 (forecast), like North America, Europe, China, Japan, Southeast Asia and India. Firstly, Memantine On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into, 5 Mg, 10 Mg, 20 Mg and Other. On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Memantine for each application, including Early to Moderate Stages and Moderate to Severe Stages.

Request for Sample @ http://www.reportsweb.com/inquiry&RW0001691639/sample

Major points from Table of Contents:

1 Memantine Market Overview

2 Global Memantine Market Competition by Manufacturers

3 Global Memantine Production, Revenue (Value) by Region (2011-2017)

4 Global Memantine Supply (Production) , Consumption, Export, Import by Regions (2011-2017)

5 Global Memantine Production, Revenue (Value) , Price Trend by Type

6 Global Memantine Market Analysis by Application

7 Global Memantine Manufacturers Profiles/Analysis

7.1 Allergan
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Memantine Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Allergan Memantine Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Lundbeck
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Memantine Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Lundbeck Memantine Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Merz Pharma
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Memantine Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Merz Pharma Memantine Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview

8 Memantine Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Memantine Market Forecast (2017-2022)

13 Research Findings and Conclusion

List of Tables and Figures

Figure Picture of Memantine
Figure Global Memantine Production (K Units) and CAGR (%) Comparison by Types (Product Category) (2012-2022)
Figure Global Memantine Production Market Share by Types (Product Category) in 2016
Figure Product Picture of 5 Mg
Table Major Manufacturers of 5 Mg
Figure Product Picture of 10 Mg
Table Major Manufacturers of 10 Mg
Figure Product Picture of 20 Mg
Table Major Manufacturers of 20 Mg
Figure Product Picture of Other
Table Major Manufacturers of Other
Figure Global Memantine Consumption (K Units) by Applications (2012-2022)
Figure Global Memantine Consumption Market Share by Applications in 2016
Figure Early to Moderate Stages Examples
Figure Moderate to Severe Stages Examples
Figure Global Memantine Market Size (Million USD), Comparison (K Units) and CAGR (%) by Regions (2012-2022)
Figure North America Memantine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Memantine Revenue (Million USD) and Growth Rate (2012-2022)
Figure China Memantine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Japan Memantine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southeast Asia Memantine Revenue (Million USD) and Growth Rate (2012-2022)
Figure India Memantine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Global Memantine Revenue (Million USD) Status and Outlook (2012-2022)
Figure Global Memantine Capacity, Production (K Units) Status and Outlook (2012-2022)
Figure Global Memantine Major Players Product Capacity (K Units) (2012-2017)
Table Global Memantine Capacity (K Units) of Key Manufacturers (2012-2017)
Table Global Memantine Capacity Market Share of Key Manufacturers (2012-2017)
Figure Global Memantine Capacity (K Units) of Key Manufacturers in 2016
Figure Global Memantine Capacity (K Units) of Key Manufacturers in 2017
Figure Global Memantine Major Players Product Production (K Units) (2012-2017)
Table Global Memantine Production (K Units) of Key Manufacturers (2012-2017)
Table Global Memantine Production Share by Manufacturers (2012-2017)
Figure 2016 Memantine Production Share by Manufacturers
Figure 2017 Memantine Production Share by Manufacturers
Figure Global Memantine Major Players Product Revenue (Million USD) (2012-2017)
Table Global Memantine Revenue (Million USD) by Manufacturers (2012-2017)
Table Global Memantine Revenue Share by Manufacturers (2012-2017)
Table 2016 Global Memantine Revenue Share by Manufacturers
Table 2017 Global Memantine Revenue Share by Manufacturers
Table Global Market Memantine Average Price (USD/Unit) of Key Manufacturers (2012-2017)

Place a Direct Purchase Order of Complete Report @ http://www.reportsweb.com/buy&RW0001691639/buy/2900

Contact Info:
Name: Sameer Joshi
Email: sales@reportsweb.com
Organization: ReportsWeb
Address: Pune, India.
Phone: +1-646-491-9876

Source URL: http://marketersmedia.com/memantine-market-share-trend-demand-and-key-manufacturers-analysis-and-forecast-to-2022/180648

For more information, please visit http://www.reportsweb.com/global-memantine-market-research-report-2017

Source: MarketersMedia

Release ID: 180648

Petrolympic Announces Closing of Private Placement

TORONTO, ON / ACCESSWIRE / March 24, 2017 / Petrolymic Ltd. (TSX-V: PCQ) (OTCQB: PCQRF) (the “Company”) is pleased to announce the closing of a non-brokered private placement (the “Offering”), consisting of 1,300,000 units (“Units”) at a price of $0.135 per Unit to raise aggregate gross proceeds of $175,500.

Each Unit consists of one common share (“Common Share”) of the Company and one Common Share purchase warrant (“Warrant”). Each Warrant entitles the holder thereof to purchase a Common Share at $0.25 per share for a period of 36 months from closing, subject to acceleration in the event that the Common Shares trade at or above $0.40 for 30 consecutive trading days.

All securities issued in connection with this Offering are subject to a four-month hold period from the date of issuance in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR OTC MARKETS GROUP INC, NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For further information, please contact:

Mendel Ekstein,
President and CEO Petrolympic Ltd.
T: 845 656-0184
E: exis@petrolympic.com

SOURCE: Petrolymic Ltd.

ReleaseID: 458125

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Northern Dynasty Minerals Ltd. – Lead Plaintiff Deadline of April 17, 2017 – NAK

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Northern Dynasty Minerals Ltd. (“Northern Dynasty”) (NYSE MKT: NAK) between September 16, 2013 and February 14, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Kirwin v. Northern Dynasty Minerals Ltd., et al. (Case No. 1:17-cv-01238) in the United States District Court for the Southern District of New York. Click here to view the complaint. To get more information, go to: http://www.zlk.com/pslra-sa/northern-dynasty-minerals-ltd, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Pebble Project carries a negative net present value; (ii) the Pebble Project is not commercially viable; and (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Northern Dynasty’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On February 14, 2017, shares of Northern Dynasty stock plummeted during intraday trading following the publication of a report on Seeking Alpha alleging that “Northern Dynasty is worthless” because its Pebble Project is not “commercially viable.”

If you suffered a loss in Northern Dynasty, you have until April 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458124

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of USANA Health Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 14, 2017 – USNA

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of USANA Health Sciences, Inc. (“USANA”) (NYSE: USNA) between March 14, 2014 and February 7, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Utah. To get more information, go to: http://www.zlk.com/pslra/usana-health-sciences-inc, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (i) the Company’s BabyCare Ltd. subsidiary had engaged in improper reimbursement practices in China; (ii) these practices constituted violations of the Foreign Corrupt Practices Act; (iii) as such, the Company’s China revenues were in part the product of unlawful conduct and unlikely to be sustainable; (iv) the foregoing conduct was likely to subject the Company to significant regulatory scrutiny; and (v) as a result of the foregoing, USANA’s public statements were materially false and misleading at all relevant times

On February 7, 2017, post-market, USANA disclosed that “[t]he Company is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. The investigation focuses on compliance with the Foreign Corrupt Practices Act…and certain conduct and policies at BabyCare, including BabyCare’s expense reimbursement policies.”

If you suffered a loss in USANA, you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458123

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ:
RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to:

http://www.zlk.com/pslra/regulus-therapeutics

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events (“SAE”) were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S. Food and Drug Administration (“FDA”) to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants’ statements about Regulus’ business and prospects were false and misleading and/or lacked a reasonable basis.

Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458120

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Under Armour, Inc. – Lead Plaintiff Deadline of April 10, 2017

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock shares of Under Armour, Inc. (“Under Armour”) (NYSE: UA, UAA) between July 24, 2014 and January 30, 2017. You are hereby notified that Levi & Korsinsky has commenced a securities class action entitled, Stenger v. Under Armour, et al., 1:17-cv-00611-GLR, in the USDC for the District of Maryland (click here to view the complaint). To get more information, go to: http://www.zlk.com/pslra/under-armour, or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period, Under Armour and certain of its officers and directors made materially false and misleading statements and/or failed to disclose that one of its largest wholesale retailers, The Sports Authority, was facing bankruptcy and, as a result of its high inventory levels at The Sports Authority, Under Armour was at risk of not meeting its revenue and profit margins.

On January 30, 2017, the Company filed a Form 8-K wherein CEO, Kevin Plank, noted that “numerous challenges and disruptions in North American retail tempered our [Company’s] fourth quarter results.” The Company also reported that its CFO was leaving the Company. Following this news, shares of Under Armour fell approximately 26% to close at $21.49 per share on January 31, 2017.

Take Action: if you suffered a
loss in Under Armour, you have until April 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 458122

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Babcock & Wilcox and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / March 24, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Babcock & Wilcox (“Babcock” or the “Company”) (NYSE: BW). Investors, who purchased or otherwise acquired Babcock shares between February 19, 2013 and March 1, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 2, 2017 lead plaintiff deadline.

If you purchased shares of Babcock during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

On March 1, 2017, Babcock & Wilcox revealed unsatisfactory fourth quarter 2016 outcomes, reporting “fourth quarter 2016 revenues of $380.0 million, a decrease of $122.7 million, or 24.4%, compared to the fourth quarter of 2015. GAAP earnings per share for the fourth quarter of 2016 were a loss of $1.47 compared to a loss per share of $0.10 for the fourth quarter of 2015.”

When this information was announced to the investing public, Babcock stock dropped, causing investors serious harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Khang & Khang LLP

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458121